original ) (raw )Multicenter, prospective, phase 2 study of maintenance bevacizumab for children and adults with NF2 -related schwannomatosis and progressive vestibular schwannoma
Lloyd Edwards
Neuro-oncology, 2023
View PDFchevron_right
A Multi-Institutional Phase II Trial of Bevacizumab for Recurrent and Refractory Meningioma
Priya Kumthekar
Neuro-Oncology Advances
View PDFchevron_right
Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2
Vanessa Merker
Otology & Neurotology, 2012
View PDFchevron_right
Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation
Rosalie Ferner
Neuro-Oncology Practice, 2016
View PDFchevron_right
The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2
Michael Slancar
Australasian Journal of Neuroscience, 2021
View PDFchevron_right
Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
KENSHO IWATATE
Neurologia medico-chirurgica
View PDFchevron_right
Bevacizumab Treatment for Vestibular Schwannoma in a Patient with Neurofibromatosis Type 2: Hearing Improvement and Tumor Shrinkage
David Rondonotti
Tumori Journal, 2015
View PDFchevron_right
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
Parv Mehta
Neuro-Oncology Advances
View PDFchevron_right
Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs
Juliana Alvarez Argote
Expert Opinion on Biological Therapy, 2018
View PDFchevron_right
Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review
Ashish Shah
Surgical neurology international, 2018
View PDFchevron_right
Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients
Vanessa Merker
PLoS ONE, 2013
View PDFchevron_right
Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2
Vianney Gaillard
Journal of Neuro-Oncology, 2015
View PDFchevron_right
Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2
Christian Hagel
Acta neurologica Scandinavica, 2015
View PDFchevron_right
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Radiosurgery and Radiation Therapy in the Management of Patients With Vestibular Schwannomas
Isabelle Germano
Neurosurgery, 2017
View PDFchevron_right
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
Annick Desjardins
Journal of Neuro-Oncology, 2012
View PDFchevron_right
Long-Term Outcomes of Vestibular Schwannomas Treated With Fractionated Stereotactic Radiotherapy: An Institutional Experience
Siddharth Kharkar
International Journal of Radiation Oncology*Biology*Physics, 2011
View PDFchevron_right
Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2
Manish Sharma
Journal of Neuro-Oncology, 2010
View PDFchevron_right
The Long-Term Outcomes of Wait-and-Scan and the Role of Radiotherapy in the Management of Vestibular Schwannomas
hakan tutar
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2014
View PDFchevron_right
Antiangiogenic agents for nonmalignant brain tumors
David Gutmann
Journal of neurological surgery. Part B, Skull base, 2013
View PDFchevron_right
Long-term outcome after highly advanced single-dose or fractionated radiotherapy in patients with vestibular schwannomas – Pooled results from 3 large German centers
Oliver Schramm
Radiotherapy and Oncology, 2015
View PDFchevron_right
LINAC radiosurgery treatment for vestibular schwannoma
Miguel Arráez-Sánchez
Neurocirugía, 2019
View PDFchevron_right
Therapeutic profile of single-fraction radiosurgery of vestibular schwannoma: unrelated malignancy predicts tumor control
Alex Muacevic
Neuro-Oncology, 2012
View PDFchevron_right
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma
Alva Weir
Journal of neuro-oncology, 2016
View PDFchevron_right
A Review of Drug Therapy in Vestibular Schwannoma
wang bin
Drug Design, Development and Therapy, 2021
View PDFchevron_right
EANO Guideline on the Diagnosis and Treatment of Vestibular Schwannoma
Otologia Joan XXIII
View PDFchevron_right
Malignancy in vestibular schwannoma after stereotactic radiotherapy: A case report and review of the literature
sami husseini
The …, 2011
View PDFchevron_right
Radiosurgery of Spinal Meningiomas and Schwannomas
Alex Muacevic
Technology in cancer …, 2012
View PDFchevron_right
On Malignant Transformation of Acoustic Neuroma/Vestibular Schwannoma 10 Years after Gamma Knife Stereotactic Radiosurgery(Skull Base 2010; 20: 381-388)
sami husseini
Skull Base, 2011
View PDFchevron_right
Analysis of risk factors associated with radiosurgery for vestibular schwannoma
Sanford Meeks
Journal of Neurosurgery, 2001
View PDFchevron_right
The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2
Pieter Pretorius
Journal of neurosurgery. Spine, 2016
View PDFchevron_right
Stereotactic radiation therapy for large vestibular schwannomas
William Vandertop
2010
View PDFchevron_right
Pseudoprogression of vestibular schwannomas after fractionated stereotactic radiation therapy
Michael Schwartz
Journal of Radiation Oncology, 2012
View PDFchevron_right
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Vanessa Merker
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
View PDFchevron_right
Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery
Kathryn Beal
Neuro-Oncology, 2013
View PDFchevron_right